Defining the ideal tumor marker for prostate cancer

Urologic Clinics of North America

Volumn 24, Issue 2, 1997, Pages 247-252

  Montie, J E ^a   Meyers, S E ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; GAMMA SEMINOPROTEIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

EID: 0030887856     PISSN: 00940143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0094-0143(05)70369-4     Document Type: Article

References (33)

1. P.C. Albertsen D.G. Fryback B.E. Storer Long-term survival among men with conservatively treated localized prostate cancer JAMA 274 1995 626
2. D.G. Altman B. Lausen W. Sauerbrei Dangers of using “optimal” cutpoints in the evaluation of prognostic factors J Natl Cancer Inst 86 1994 829
3. M.C. Benson I.S. Whant A. Pantuck Prostate specific antigen density: A means of distinguishing benign prostatic hypertrophy and prostate cancer J Urol 147 1992 815
4. H.B. Burke D.E. Henson Criteria for prognostic factors and for an enhanced prognostic system Cancer 72 1993 3131
5. W.J. Catalona D.S. Smith R.L. Wolfert Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening JAMA 274 1995 1214
6. W.H. Cooner Definition of the ideal tumor marker Urol Clin North Am 20 1993 575
7. R.R. Gatling Prostate carcinoma: An autopsy evaluation of age, tumor grade and therapy on tumor biology South Med J 83 1990 782
8. A.B. Gutman E.B. Gutman An “acid” phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland J Clin Invest 17 1938 473
9. M. Hara T. Innore T. Fukulyama Some physicochemical characteristics of gamma-seminoprotein, an antigenic component specific for human seminal plasma Nippon Hoigaku Zasshi 25 1971 322
10. K.W. Lam P. Lee T. Eastlan Antigenic and molecular relationship of human prostatic acid phosphatase isoenzymes Invest Urol (Berl) 18 1980 209
11. P.H. Lange D.J. Lightner E. Medini The effect of radiation therapy after radical prostatectomy in patients with elevated prostate-specific antigen levels J Urol 144 1990 927
12. B.D. Leibman O. Dillioglugil T.M. Wheeler Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level Cancer 76 1995 2530
13. J.E. Montie Current prognostic factors for prostate carcinoma Cancer 78 1996 341
14. J.E. Montie Follow-up after radical prostatectomy or radiation therapy for prostate cancer Urol Clin North Am 21 1994 673
15. G.P. Murphy The second Stanford conference on international standardization of prostate specific antigen assays Cancer 75 1995 122
16. J.E. Oesterling S.J. Jacobsen C.G. Chute Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age specific reference ranges JAMA 270 1993 860
17. J.E. Oesterling S.J. Jacobsen G.G. Klee Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios J Urol 154 1995 1090
18. J.E. Oesterling S.K. Martin E.J. Bergstralh The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer JAMA 269 1993 57
19. Oesterling JE, Wojno KJ, England B, et al: A comparison of free to total PSA (f/t) ratio to total PSA for distinguishing benign prostatic hyperplasia (BPH) from prostate cancer (CaP) using the Abbott AxSYM system [abstract 240]. Proceedings of the American Urological Association 155(suppl):370A
20. M. Ohori J.K. Dunn P.T. Scardino Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 46 1995 666
21. L.D. Papsidero M.C. Wang L.A. Valenzuela A prostate antigen in sera of prostate cancer patients Cancer Res 40 1980 2428
22. A.W. Partin J.E. Oesterling The clinical usefulness of prostate specific antigen: Update 1994 J Urol 152 1994 1358
23. A.W. Partin J. Yoo H.B. Carter The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer J Urol 150 1993 110
24. A.W. Partin J.D. Pearson P.K. Landis Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases Urol 43 1994 649
25. T.M. Pisansky H. Zincke V.J. Suman Correlation of pretherapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens Int J Radiat Oncol Biol Phys 34 1996 33
26. C.G. Roehrborn G.J. Pickens T. Carmody Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population Urology 47 1996 59
27. H.C. Ruckle G.G. Klee J.E. Oesterling Prostate-specific antigen: Concepts for staging prostate cancer and monitoring response to therapy Mayo Clin Proc 69 1994 69
28. W.A. Sakr D.J. Grignon J.D. Crissman High grade prostatic intraepithelial hyperplasia and prostatic adenocarcinoma between ages 20–69: An autopsy study of 249 cases In Vivo 8 1994 439
29. P.K. Schultz W.K. Kelly C. Begg Post-therapy change in prostate-specific antigen levels as a clinical trial endpoint in hormone-refractory prostatic cancer: A trial with 10-Ethyl-Deaza-Aminopterin Urology 44 1994 237
30. S. Sell Cancer markers ed 2 Moossa A.R. Schimpff S.C. Robson M.C. Comprehensive Textbook of Oncology vol 1 1991 Williams & Wilkins Baltimore 225
31. S.E. Shild S.J. Buskirk J.S. Robinow The results of radiotherapy for isolated elevation of serum PSA levels following radical prostatectomy Int J Radiat Oncol Biol Phys 23 1992 141
32. R. Simon D.G. Altman Statistical aspects of prognostic factor studies in oncology Br J Cancer 69 1994 979
33. M.C. Wang L.A. Valenzuela G.P. Murphy Purification of human prostate specific antigen Invest Urol 17 1979 159